Agenda
- Welcome and Introduction
- Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer – Juan C. Hernandez-Prera, MD
- RET Fusions or Mutations
- Testing Strategies for Actionable Genomic Alterations in Thyroid Cancer
- Overview, Rationale, and Guidance on Testing for Rare Genomic Fusions in NSCLC – Jeremy Segal, MD, PhD
- NTRK Fusions
- RET Fusions
- Testing Strategies for Rare Genomic Fusions in Lung Cancer
- Master Class Interactive Case Discussions – Faculty Panel
- Lung Cancer
- Thyroid Cancer
- Final Audience Question and Answer Session
Events
Date / Time
Event Details
Faculty
Co-Chair
Juan C. Hernandez-Prera, MD
Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida
Co-Chair
Faculty
Taylor Bronson, MD
Assistant Professor
Department of Pathology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Faculty
Farres Obeidin, MD
Assistant Professor
Department of Pathology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
Faculty
Peter Sadow, MD, PhD
Associate Professor of Pathology
Harvard Medical School
Director, Head and Neck Pathology
Massachusetts General Hospital
Boston, Massachusetts
Faculty
Melissa Tjota, MD, PhD
Assistant Professor
Department of Pathology
University of Chicago Medical Center
Chicago, Illinois
Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patients with lung or thyroid cancers.
Target Audience
This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, and other healthcare professionals who care for patients with lung or thyroid cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
- Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
- Formulate strategies for integrating TRK and RET inhibitors into the management of eligible patients with NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
- Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy
- Manage treatment-related symptoms associated with the treatment of RET altered or NTRK fusion–positive cancer
- Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials
Accreditation
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.